DrugPatentWatch
DrugPatentWatch.com is proud to announce the addition of a vital new feature to it's rich collection of drug patent intelligence tools: tentative FDA approvals.
The addition of tentative FDA approvals complements existing indicators such as Paragraph IV challenges, patent claim types, and patent maintenance, reexamination, interference and disclaimer in providing a robust overview of the trends in pharmaceutical sales by branded and generic firms. Tentative FDA approvals can indicate which generic companies are poised to launch generic drugs on the expiration of patents and exclusivities covering branded drugs -- this vital knowledge may aid investors in their decisions and help distributors and pharmacies plan their purchases.
Other datasets include:
- Impending drug patent expirations
- Annual sales
- Drug therapeutic class
- Paragraph IV challenges
- Premature patent expiration due to lack of maintenance fee payment
- Patent reexaminations
- Patent interferences
- Patent disclaimers
- Full-text drug patent PDFs
- Drug patent claim types (use, compound, formulation, etc.)
Detailed previews and a site tour are available at http://www.DrugPatentWatch.com
Photo:
http://www.prlog.org/
